By continuing to browse the site you are agreeing to our use of cookies and similar tracking technologies described in our privacy policy.

Choose which cookies you allow
Necessary Required for the site to work, such as remembering this choice. Always active

AASLD Logo
IDSA Logo
Resource Library
  • Home
    • Table of Contents
    • Introductions
    • Methods
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
  • Test, Evaluate, Monitor
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
  • Treatment-Naive
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
    • Genotype 1
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
    • Genotype 2
      • GT2: No Cirrhosis
      • GT2: Compensated
    • Genotype 3
      • GT3: No Cirrhosis
      • GT3: Compensated
    • Genotype 4
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
  • Treatment-Experienced Patients
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
  • Unique & Key Populations
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
    • PWID, MSM & Corrections
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
  • About
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
AASLD Logo
IDSA Logo
    • Table of Contents
    • Introductions
      • Methods Table 1
      • Methods Table 2
      • Methods Table 3 Abbreviations
      • Table 4. Child-Turcotte-Pugh (CTP) Classification of Cirrhosis Severity
    • References
    • Testing and Linkage to Care
    • When and in Whom to Initiate HCV Therapy
    • Cost, Reimbursement, and Cost-Effectiveness
    • Monitoring Persons Who Are Starting HCV Treatment, Are on Treatment, or Have Completed Antiviral Therapy
    • Incomplete Adherence
    • HCV Resistance Primer
    • Simplified: No Cirrhosis
    • Simplified: Compensated Cirrhosis
    • Decompensated Cirrhosis
      • GT1a: No Cirrhosis
      • GT1a: Compensated
      • GT1b: No Cirrhosis
      • GT1b: Compensated
      • GT2: No Cirrhosis
      • GT2: Compensated
      • GT3: No Cirrhosis
      • GT3: Compensated
      • GT4: No Cirrhosis
      • GT4: Compensated
    • Genotype 5 or 6
    • SOF-Based and ELB/GRZ Treatment Failures
    • G/P Treatment Failures
    • Multiple DAA Treatment Failures
    • Retreatment in Persons With Decompensated Cirrhosis
    • HIV/HCV Coinfection
    • Decompensated Cirrhosis
    • Persons With Hepatocellular Carcinoma 
    • Post Liver Transplant
    • Organs from HCV-Viremic Donors
    • Renal Impairment
    • Kidney Transplant
    • Acute Infection
    • HCV in Pregnancy
    • HCV in Children
      • People Who Inject Drugs
      • Men Who Have Sex With Men
      • Correctional Settings
    • Announcements
    • Supporting Organizations
    • HCV Guidance Panel
    • Disclosures
    • Process
    • Citing and Permissions
    • Website Policies
    • Contact Us
Resource Library
  • CD4+ count-guided interruption of antiretroviral treatment

    May 18, 2017
  • US Preventive Services Task Force. Screening for HIV: US Preventive Services Task Force recommendation statement

    May 3, 2017
  • Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease

    May 3, 2017
  • Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic

    May 3, 2017
  • Rapid progression to decompensated cirrhosis, liver transplant, and death in HIV-infected men after primary hepatitis C virus infection

    May 3, 2017
  • Factors affecting liver fibrosis in human immunodeficiency virus and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy

    May 3, 2017
AASLD Logo
IDSA Logo
  • Test, Evaluate, Monitor
  • Treatment-Naive
  • Treatment-Experienced Patients
  • Key Populations With HCV Infection
  • Resource Library
  • About Us
  • Announcements
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Accessibility

© 2025 HCV Guidelines All right reserved.

Website by Yoko Co